Trials / Completed
CompletedNCT01594502
Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies
R01 CA155301: Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 139 (actual)
- Sponsor
- University of Illinois at Chicago · Academic / Other
- Sex
- Male
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to apply cutting-edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5α-reductase inhibitor chemoprevention as well as the risk of prostate cancer among men with negative biopsies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dutasteride | 0.5 mg daily |
| DRUG | Placebo | Placebo Comparator |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2015-11-01
- Completion
- 2016-07-01
- First posted
- 2012-05-09
- Last updated
- 2020-10-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01594502. Inclusion in this directory is not an endorsement.